Breast Neoplasms
Conditions
Brief summary
This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR +/HER2- breast cancer patients with poor response to previous chemotherapy.
Interventions
DRUGChidamide combined with exemestane (+/- goserelin)
Chidamide combined with exemestane (+/- goserelin)
DRUGChemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Sponsors
Shengjing Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following: 1. previous oophorectomy, or age ≥ 60 years; 2. age \< 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels; 3. premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study; * all patients were confirmed by histopathology as estrogen receptor (ER) positive (\> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria; * tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD; * KPS score ≥ 70 points; * organ function level must meet the following requirements: 1. bone marrow function ANC ≥ 1.5 × 109/L (14 without growth factors); PLT ≥ 100 × 109/L (7 without corrective treatment); Hb ≥ 100 g/L (7) without corrective treatment; 2. liver and kidney function TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); * able to undergo needle biopsy; * voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up
Exclusion criteria
* received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); * received any other anti-tumor therapy at the same time; * breast cancer, inflammatory breast cancer or occult breast cancer; * stage IV breast cancer; * breast cancer without histopathological diagnosis;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR | Up to approximately 48 months |
Secondary
| Measure | Time frame |
|---|---|
| Residual tumor burden (RCB) classification | Up to approximately 48 months |
| Total breast pathological complete remission rate (bpCR) | Up to approximately 48 months |
| PEPI classification | Up to approximately 48 months |
| pCR：Upon completion of neoadjuvant therapy and surgery, there was no residual invasive carcinoma present in the pathologic assessment of the resected breast cancer samples stained with hematoxylin and eosin and all ipsilateral lymph node samples. | Up to approximately 48 months |
| patient-reported outcome（PRO）：evaluate daily functioning and health outcomes from the patient's perspective by HRQOL | Up to approximately 48 months |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to approximately 48 months |
| Number of participants with treatment-related serious adverse event as assessed by CTCAE v5.0 | Up to approximately 48 months |
| Breast-conserving rate | Up to approximately 48 months |
Outcome results
None listed